elisas euroimmun Search Results


commercially available elisa kit anca-profil (igg)  (EUROIMMUN)
90
EUROIMMUN commercially available elisa kit anca-profil (igg)
Commercially Available Elisa Kit Anca Profil (Igg), supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/commercially+available+elisa+kit+anca+profil++igg+/pm15308872-47-27-31
Average 90 stars, based on 1 article reviews
commercially available elisa kit anca-profil (igg) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
elisa reagent wells  (EUROIMMUN)
90
EUROIMMUN elisa reagent wells
Elisa Reagent Wells, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/elisa+reagent+wells/pmc04304788-185-1-28
Average 90 stars, based on 1 article reviews
elisa reagent wells - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
elisa for immunoglobulin g (igg) antibodies to b. burgdorferi whole-cell lysate supplemented with recombinant vlse protein  (EUROIMMUN)
90
EUROIMMUN elisa for immunoglobulin g (igg) antibodies to b. burgdorferi whole-cell lysate supplemented with recombinant vlse protein
Antibody reactivity to endothelial cell growth factor (ECGF). A, Level and frequency of immunoglobulin G (IgG) reactivity to ECGF, as determined with enzyme-linked <t>immunosorbent</t> <t>(ELISA),</t> in healthy controls without a history or serologic evidence of past Lyme disease (n = 50), patients with a range of early to late manifestations of active Lyme disease (n = 79), posttreatment Lyme disease healthy (PTLDH) individuals (n = 69), and patients with posttreatment Lyme disease syndrome (PTLDS) (n = 74). Horizontal bars indicate the mean for each group; gray section, area within 3 standard deviations of the mean for the healthy control group, above which values are considered positive. Compared with healthy controls, the active Lyme disease cohort had a significantly higher level and frequency of antibody reactivity to ECGF (P < .001). Compared with the active Lyme disease group, the level and frequency of antibody reactivity to ECGF were significantly lower in both posttreatment Lyme disease groups (PTLDS and PTLDH) (P < .001 for each). There was no significant difference in anti-ECGF antibody reactivity between the PTLDS and PTLDH cohorts (P > .99). B, Level and frequency of IgG reactivity to ECGF in healthy controls (n = 50) and in subgroups of patients with active Lyme disease, representing early to late manifestations of Lyme disease, including single erythema migrans (EM) (n = 18), multiple EM (n = 17), early neurologic (n = 16), late neurologic (n = 16), and arthritis (n = 12). Compared with the healthy cohort, there was a significantly higher level and frequency of antibody response in the multiple EM (P < .001), early neurologic (P < .001), late neurologic (P < .001), and arthritis (P < .001) groups but not the single EM group. There were no significant differences among the multiple EM, early neurologic, late neurologic, and arthritis groups. Abbreviation: OD450, optical density was measured at 450 nm.
Elisa For Immunoglobulin G (Igg) Antibodies To B. Burgdorferi Whole Cell Lysate Supplemented With Recombinant Vlse Protein, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/elisa+immunoglobulin+g/pmc04643484-35-8-26
Average 90 stars, based on 1 article reviews
elisa for immunoglobulin g (igg) antibodies to b. burgdorferi whole-cell lysate supplemented with recombinant vlse protein - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
elisa  (EUROIMMUN)
90
EUROIMMUN elisa
Antibody reactivity to endothelial cell growth factor (ECGF). A, Level and frequency of immunoglobulin G (IgG) reactivity to ECGF, as determined with enzyme-linked <t>immunosorbent</t> <t>(ELISA),</t> in healthy controls without a history or serologic evidence of past Lyme disease (n = 50), patients with a range of early to late manifestations of active Lyme disease (n = 79), posttreatment Lyme disease healthy (PTLDH) individuals (n = 69), and patients with posttreatment Lyme disease syndrome (PTLDS) (n = 74). Horizontal bars indicate the mean for each group; gray section, area within 3 standard deviations of the mean for the healthy control group, above which values are considered positive. Compared with healthy controls, the active Lyme disease cohort had a significantly higher level and frequency of antibody reactivity to ECGF (P < .001). Compared with the active Lyme disease group, the level and frequency of antibody reactivity to ECGF were significantly lower in both posttreatment Lyme disease groups (PTLDS and PTLDH) (P < .001 for each). There was no significant difference in anti-ECGF antibody reactivity between the PTLDS and PTLDH cohorts (P > .99). B, Level and frequency of IgG reactivity to ECGF in healthy controls (n = 50) and in subgroups of patients with active Lyme disease, representing early to late manifestations of Lyme disease, including single erythema migrans (EM) (n = 18), multiple EM (n = 17), early neurologic (n = 16), late neurologic (n = 16), and arthritis (n = 12). Compared with the healthy cohort, there was a significantly higher level and frequency of antibody response in the multiple EM (P < .001), early neurologic (P < .001), late neurologic (P < .001), and arthritis (P < .001) groups but not the single EM group. There were no significant differences among the multiple EM, early neurologic, late neurologic, and arthritis groups. Abbreviation: OD450, optical density was measured at 450 nm.
Elisa, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/elisa/pmc04891486-76-7-8
Average 90 stars, based on 1 article reviews
elisa - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
beta-amyloid (1-40) elisa  (EUROIMMUN)
90
EUROIMMUN beta-amyloid (1-40) elisa
a) Epitope mapping of both mAbs ADxNGCI2 and ADxNGCT1 was performed with overlapping synthetic peptides, ranging from R51 to D78. b) Specificity of the mAbs ADxNGCI2 and ADxNGCT1 was evaluated by western blot analysis where both synthetic full-length neurogranin, as well as a synthetic neurogranin peptide that is truncated at P75, were included in the gel electrophoresis, next to human collagen type I, III, and IV. ADxNGCI2 positively stained both synthetic peptides, whereas ADxNGCT1 only labeled the truncated form. None of the mAbs detected the collagen proteins. c) To confirm the specificity of the prototype <t>ELISA</t> towards neurogranin species truncated at P75, different concentrations were analyzed of several synthetic neurogranin peptides that differ in their C-terminus, i.e., intact (Peptide intact C-term) or either truncated at P75 (Peptide trunc P75) or at S76 (Peptide trunc S76).
Beta Amyloid (1 40) Elisa, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/beta+amyloid+1+42+elisa/pmc04981899-124-22-26
Average 90 stars, based on 1 article reviews
beta-amyloid (1-40) elisa - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
commercial elisa kit  (EUROIMMUN)
90
EUROIMMUN commercial elisa kit
The OD of sera of <t>C.</t> <t>trachomatis</t> suspected patients in rOMP2 coated <t>ELISA</t> plate wells.
Commercial Elisa Kit, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/commercial+elisa+kits/pmc04419049-72-19-18
Average 90 stars, based on 1 article reviews
commercial elisa kit - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
serum and salivary anti-dsg 1 and 3 elisa  (EUROIMMUN)
90
EUROIMMUN serum and salivary anti-dsg 1 and 3 elisa
The OD of sera of <t>C.</t> <t>trachomatis</t> suspected patients in rOMP2 coated <t>ELISA</t> plate wells.
Serum And Salivary Anti Dsg 1 And 3 Elisa, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/elisa+test/pmc04320921-53-2-16
Average 90 stars, based on 1 article reviews
serum and salivary anti-dsg 1 and 3 elisa - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti-zika virus elisa (igm)  (EUROIMMUN)
90
EUROIMMUN anti-zika virus elisa (igm)
The OD of sera of <t>C.</t> <t>trachomatis</t> suspected patients in rOMP2 coated <t>ELISA</t> plate wells.
Anti Zika Virus Elisa (Igm), supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/zikv+igm+elisa/pmc04998508-22-45-56
Average 90 stars, based on 1 article reviews
anti-zika virus elisa (igm) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti-hsv-2 (gg2) elisa (igg)  (EUROIMMUN)
90
EUROIMMUN anti-hsv-2 (gg2) elisa (igg)
Data collection
Anti Hsv 2 (Gg2) Elisa (Igg), supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/antihsv+2+elisa/pmc05109686-55-2-6
Average 90 stars, based on 1 article reviews
anti-hsv-2 (gg2) elisa (igg) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
standard elisa kit  (EUROIMMUN)
90
EUROIMMUN standard elisa kit
Data collection
Standard Elisa Kit, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/standard+elisa+kit/pmc05283559-143-11-14
Average 90 stars, based on 1 article reviews
standard elisa kit - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
igg elisa kits  (EUROIMMUN)
90
EUROIMMUN igg elisa kits
Results <t>of</t> <t>IgG</t> <t>ELISA</t> with recombinant SAG1, SAG2, and SAG3 in human sera. P, IgG positive; Non, non-relative (cases with different infectious diseases but not toxoplasmosis); N, negative reactions (Epstein-Barr virus, Varicella zoster virus, Herpes simplex virus, rubella, measles, Helicobacter pylori , cytomegalovirus, malaria, Echinococcus granulosus , Hymenolepis nana , Leishmania , and rheumatoid factor).
Igg Elisa Kits, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/igg+elisa+kits/pmc04028450-40-15-18
Average 90 stars, based on 1 article reviews
igg elisa kits - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
elisa kits  (EUROIMMUN)
90
EUROIMMUN elisa kits
Results <t>of</t> <t>IgG</t> <t>ELISA</t> with recombinant SAG1, SAG2, and SAG3 in human sera. P, IgG positive; Non, non-relative (cases with different infectious diseases but not toxoplasmosis); N, negative reactions (Epstein-Barr virus, Varicella zoster virus, Herpes simplex virus, rubella, measles, Helicobacter pylori , cytomegalovirus, malaria, Echinococcus granulosus , Hymenolepis nana , Leishmania , and rheumatoid factor).
Elisa Kits, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas+euroimmun/elisa+kit/pmc03443480-78-13-15
Average 90 stars, based on 1 article reviews
elisa kits - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Antibody reactivity to endothelial cell growth factor (ECGF). A, Level and frequency of immunoglobulin G (IgG) reactivity to ECGF, as determined with enzyme-linked immunosorbent (ELISA), in healthy controls without a history or serologic evidence of past Lyme disease (n = 50), patients with a range of early to late manifestations of active Lyme disease (n = 79), posttreatment Lyme disease healthy (PTLDH) individuals (n = 69), and patients with posttreatment Lyme disease syndrome (PTLDS) (n = 74). Horizontal bars indicate the mean for each group; gray section, area within 3 standard deviations of the mean for the healthy control group, above which values are considered positive. Compared with healthy controls, the active Lyme disease cohort had a significantly higher level and frequency of antibody reactivity to ECGF (P < .001). Compared with the active Lyme disease group, the level and frequency of antibody reactivity to ECGF were significantly lower in both posttreatment Lyme disease groups (PTLDS and PTLDH) (P < .001 for each). There was no significant difference in anti-ECGF antibody reactivity between the PTLDS and PTLDH cohorts (P > .99). B, Level and frequency of IgG reactivity to ECGF in healthy controls (n = 50) and in subgroups of patients with active Lyme disease, representing early to late manifestations of Lyme disease, including single erythema migrans (EM) (n = 18), multiple EM (n = 17), early neurologic (n = 16), late neurologic (n = 16), and arthritis (n = 12). Compared with the healthy cohort, there was a significantly higher level and frequency of antibody response in the multiple EM (P < .001), early neurologic (P < .001), late neurologic (P < .001), and arthritis (P < .001) groups but not the single EM group. There were no significant differences among the multiple EM, early neurologic, late neurologic, and arthritis groups. Abbreviation: OD450, optical density was measured at 450 nm.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Association of Immune Response to Endothelial Cell Growth Factor With Early Disseminated and Late Manifestations of Lyme Disease but Not Posttreatment Lyme Disease Syndrome

doi: 10.1093/cid/civ638

Figure Lengend Snippet: Antibody reactivity to endothelial cell growth factor (ECGF). A, Level and frequency of immunoglobulin G (IgG) reactivity to ECGF, as determined with enzyme-linked immunosorbent (ELISA), in healthy controls without a history or serologic evidence of past Lyme disease (n = 50), patients with a range of early to late manifestations of active Lyme disease (n = 79), posttreatment Lyme disease healthy (PTLDH) individuals (n = 69), and patients with posttreatment Lyme disease syndrome (PTLDS) (n = 74). Horizontal bars indicate the mean for each group; gray section, area within 3 standard deviations of the mean for the healthy control group, above which values are considered positive. Compared with healthy controls, the active Lyme disease cohort had a significantly higher level and frequency of antibody reactivity to ECGF (P < .001). Compared with the active Lyme disease group, the level and frequency of antibody reactivity to ECGF were significantly lower in both posttreatment Lyme disease groups (PTLDS and PTLDH) (P < .001 for each). There was no significant difference in anti-ECGF antibody reactivity between the PTLDS and PTLDH cohorts (P > .99). B, Level and frequency of IgG reactivity to ECGF in healthy controls (n = 50) and in subgroups of patients with active Lyme disease, representing early to late manifestations of Lyme disease, including single erythema migrans (EM) (n = 18), multiple EM (n = 17), early neurologic (n = 16), late neurologic (n = 16), and arthritis (n = 12). Compared with the healthy cohort, there was a significantly higher level and frequency of antibody response in the multiple EM (P < .001), early neurologic (P < .001), late neurologic (P < .001), and arthritis (P < .001) groups but not the single EM group. There were no significant differences among the multiple EM, early neurologic, late neurologic, and arthritis groups. Abbreviation: OD450, optical density was measured at 450 nm.

Article Snippet: Forty-six patients were seropositive with a commercial enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) antibodies to B. burgdorferi whole-cell lysate supplemented with recombinant VlsE protein (Euroimmun) [ 11 ].

Techniques: Enzyme-linked Immunosorbent Assay

a) Epitope mapping of both mAbs ADxNGCI2 and ADxNGCT1 was performed with overlapping synthetic peptides, ranging from R51 to D78. b) Specificity of the mAbs ADxNGCI2 and ADxNGCT1 was evaluated by western blot analysis where both synthetic full-length neurogranin, as well as a synthetic neurogranin peptide that is truncated at P75, were included in the gel electrophoresis, next to human collagen type I, III, and IV. ADxNGCI2 positively stained both synthetic peptides, whereas ADxNGCT1 only labeled the truncated form. None of the mAbs detected the collagen proteins. c) To confirm the specificity of the prototype ELISA towards neurogranin species truncated at P75, different concentrations were analyzed of several synthetic neurogranin peptides that differ in their C-terminus, i.e., intact (Peptide intact C-term) or either truncated at P75 (Peptide trunc P75) or at S76 (Peptide trunc S76).

Journal: Journal of Alzheimer's Disease

Article Title: The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease

doi: 10.3233/JAD-160227

Figure Lengend Snippet: a) Epitope mapping of both mAbs ADxNGCI2 and ADxNGCT1 was performed with overlapping synthetic peptides, ranging from R51 to D78. b) Specificity of the mAbs ADxNGCI2 and ADxNGCT1 was evaluated by western blot analysis where both synthetic full-length neurogranin, as well as a synthetic neurogranin peptide that is truncated at P75, were included in the gel electrophoresis, next to human collagen type I, III, and IV. ADxNGCI2 positively stained both synthetic peptides, whereas ADxNGCT1 only labeled the truncated form. None of the mAbs detected the collagen proteins. c) To confirm the specificity of the prototype ELISA towards neurogranin species truncated at P75, different concentrations were analyzed of several synthetic neurogranin peptides that differ in their C-terminus, i.e., intact (Peptide intact C-term) or either truncated at P75 (Peptide trunc P75) or at S76 (Peptide trunc S76).

Article Snippet: CSF levels of total-tau, Aβ 1-42 and Aβ 1-40 were re-analyzed during this study, using the total-tau ELISA, Beta-Amyloid (1-42) ELISA and Beta-Amyloid (1-40) ELISA by Euroimmun.

Techniques: Western Blot, Nucleic Acid Electrophoresis, Staining, Labeling, Enzyme-linked Immunosorbent Assay

The OD of sera of C. trachomatis suspected patients in rOMP2 coated ELISA plate wells.

Journal: Iranian Journal of Microbiology

Article Title: Using recombinant Chlamydia trachomatis OMP2 as antigen in diagnostic ELISA test

doi:

Figure Lengend Snippet: The OD of sera of C. trachomatis suspected patients in rOMP2 coated ELISA plate wells.

Article Snippet: There were 7 positive samples (3.83%) and 173 negative samples (96.1%) of 180 suspected C. trachomatis sera by Euroimmun commercial ELISA kit.

Techniques: Enzyme-linked Immunosorbent Assay

The sera OD for C. trachomatis suspected patients in Euroimmun commercial ELISA kit Since the P-Value = 0.88 is greater than the significance level of a = 0.05, so there is no significant relationship between the rOMP2 and Euroimmun commercial ELISA kit.

Journal: Iranian Journal of Microbiology

Article Title: Using recombinant Chlamydia trachomatis OMP2 as antigen in diagnostic ELISA test

doi:

Figure Lengend Snippet: The sera OD for C. trachomatis suspected patients in Euroimmun commercial ELISA kit Since the P-Value = 0.88 is greater than the significance level of a = 0.05, so there is no significant relationship between the rOMP2 and Euroimmun commercial ELISA kit.

Article Snippet: There were 7 positive samples (3.83%) and 173 negative samples (96.1%) of 180 suspected C. trachomatis sera by Euroimmun commercial ELISA kit.

Techniques: Enzyme-linked Immunosorbent Assay

Results of ELISA test with rOMP2 on 192 sera samples of C. trachomatis suspected patients.

Journal: Iranian Journal of Microbiology

Article Title: Using recombinant Chlamydia trachomatis OMP2 as antigen in diagnostic ELISA test

doi:

Figure Lengend Snippet: Results of ELISA test with rOMP2 on 192 sera samples of C. trachomatis suspected patients.

Article Snippet: There were 7 positive samples (3.83%) and 173 negative samples (96.1%) of 180 suspected C. trachomatis sera by Euroimmun commercial ELISA kit.

Techniques: Enzyme-linked Immunosorbent Assay

Results of ELISA test with Euroimmun commercial ELISA kit on 180 sera samples of C. trachomatis suspected patients.

Journal: Iranian Journal of Microbiology

Article Title: Using recombinant Chlamydia trachomatis OMP2 as antigen in diagnostic ELISA test

doi:

Figure Lengend Snippet: Results of ELISA test with Euroimmun commercial ELISA kit on 180 sera samples of C. trachomatis suspected patients.

Article Snippet: There were 7 positive samples (3.83%) and 173 negative samples (96.1%) of 180 suspected C. trachomatis sera by Euroimmun commercial ELISA kit.

Techniques: Enzyme-linked Immunosorbent Assay

Results of ELISA with Euroimmun commercial kit and C. trachomatis rOMP2.

Journal: Iranian Journal of Microbiology

Article Title: Using recombinant Chlamydia trachomatis OMP2 as antigen in diagnostic ELISA test

doi:

Figure Lengend Snippet: Results of ELISA with Euroimmun commercial kit and C. trachomatis rOMP2.

Article Snippet: There were 7 positive samples (3.83%) and 173 negative samples (96.1%) of 180 suspected C. trachomatis sera by Euroimmun commercial ELISA kit.

Techniques: Enzyme-linked Immunosorbent Assay

Data collection

Journal: BMC Health Services Research

Article Title: Design of the Indian NCA study (Indian national collaboration on AIDS): a cluster randomized trial to evaluate the effectiveness of integrated care centers to improve HIV outcomes among men who have sex with men and persons who inject drugs in India

doi: 10.1186/s12913-016-1905-5

Figure Lengend Snippet: Data collection

Article Snippet: HSV-2 , Anti-HSV-2 (gG2) ELISA (IgG), Euroimmun Medizinische Labordiagnostika AG, Lubeck, Germany , x , .

Techniques: Medications, Injection, Virus, Flow Cytometry, Enzyme-linked Immunosorbent Assay

Results of IgG ELISA with recombinant SAG1, SAG2, and SAG3 in human sera. P, IgG positive; Non, non-relative (cases with different infectious diseases but not toxoplasmosis); N, negative reactions (Epstein-Barr virus, Varicella zoster virus, Herpes simplex virus, rubella, measles, Helicobacter pylori , cytomegalovirus, malaria, Echinococcus granulosus , Hymenolepis nana , Leishmania , and rheumatoid factor).

Journal: The Korean Journal of Parasitology

Article Title: Evaluation of Recombinant SAG1, SAG2, and SAG3 Antigens for Serodiagnosis of Toxoplasmosis

doi: 10.3347/kjp.2014.52.2.137

Figure Lengend Snippet: Results of IgG ELISA with recombinant SAG1, SAG2, and SAG3 in human sera. P, IgG positive; Non, non-relative (cases with different infectious diseases but not toxoplasmosis); N, negative reactions (Epstein-Barr virus, Varicella zoster virus, Herpes simplex virus, rubella, measles, Helicobacter pylori , cytomegalovirus, malaria, Echinococcus granulosus , Hymenolepis nana , Leishmania , and rheumatoid factor).

Article Snippet: Serum samples were collected from different laboratories around Shiraz and Tehran using commercial IgG and IgM ELISA kits (Euroimmun, Lubeck, Germany).

Techniques: Enzyme-linked Immunosorbent Assay, Recombinant, Virus

Results of IgM ELISA with recombinant SAG1, SAG2, and SAG3 in human sera. P, IgM positive; N, IgM negative. Cut-off value; 0.60 (SAG1), 0.31 (SAG2), and 0.44 (SAG3), respectively.

Journal: The Korean Journal of Parasitology

Article Title: Evaluation of Recombinant SAG1, SAG2, and SAG3 Antigens for Serodiagnosis of Toxoplasmosis

doi: 10.3347/kjp.2014.52.2.137

Figure Lengend Snippet: Results of IgM ELISA with recombinant SAG1, SAG2, and SAG3 in human sera. P, IgM positive; N, IgM negative. Cut-off value; 0.60 (SAG1), 0.31 (SAG2), and 0.44 (SAG3), respectively.

Article Snippet: Serum samples were collected from different laboratories around Shiraz and Tehran using commercial IgG and IgM ELISA kits (Euroimmun, Lubeck, Germany).

Techniques: Enzyme-linked Immunosorbent Assay, Recombinant